Alnylam Pharmaceuticals to Showcase New Analyses at Heart Failure 2026 Highlighting Consistent Clinical Profile of Vutrisiran in ATTR-CM

Alnylam Pharmaceuticals to Showcase New Analyses at Heart Failure 2026 Highlighting the Consistent Clinical Profile of Vutrisiran in ATTR-CM Alnylam Pharmaceuticals (Nasdaq: ALNY) has announced that it will present a…

Read MoreAlnylam Pharmaceuticals to Showcase New Analyses at Heart Failure 2026 Highlighting Consistent Clinical Profile of Vutrisiran in ATTR-CM

Armatus Launches Scalable Potency Assay Platform to Advance Next-Generation Gene Silencing Therapies

Armatus Unveils Scalable Potency Assay Platform to Advance Next-Generation Gene Silencing Therapies Armatus Bio, a late-preclinical biotechnology company focused on developing vectorized RNA interference (RNAi) therapies for neuromuscular disorders, has…

Read MoreArmatus Launches Scalable Potency Assay Platform to Advance Next-Generation Gene Silencing Therapies

Takeda Pharmaceutical Company Reports Positive Topline Data from Pivotal Phase 2/3 Trial of TAK-881 in Primary Immunodeficiency Disease

Takeda Pharmaceutical Company Reports Positive Topline Results from Pivotal Phase 2/3 Study of TAK-881 in Primary Immunodeficiency Disease Takeda Pharmaceutical Company (TSE:4502/NYSE:TAK) has reported positive topline results from its pivotal…

Read MoreTakeda Pharmaceutical Company Reports Positive Topline Data from Pivotal Phase 2/3 Trial of TAK-881 in Primary Immunodeficiency Disease

Satellite Bio Secures U.S. Food and Drug Administration Rare Pediatric Disease Designation for SB-101 in Urea Cycle Disorders

Satellite Bio Secures U.S. Food and Drug Administration Rare Pediatric Disease Designation for SB-101 in Urea Cycle Disorders Satellite Biosciences has announced a significant regulatory milestone, revealing that the U.S.…

Read MoreSatellite Bio Secures U.S. Food and Drug Administration Rare Pediatric Disease Designation for SB-101 in Urea Cycle Disorders